Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | POLD1 | P28340 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24971026 | 1.00 | POLG (0.43) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327416 | 0.94 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327101 | 0.94 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327017 | 0.94 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327251 | 0.87 | POLG (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327435 | 0.87 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL24973021 | 0.86 | DTYMK (0.41) | P2RY2POLBDTYMK | |
| SCHEMBL18855500 | 0.86 | POLG (0.45) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18866693 | 0.86 | POLG (0.45) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18844560 | 0.86 | POLG (0.45) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLG 89/4885P2RY2 1336/4885P2RY4 1162/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLG 89/4885P2RY2 1336/4885P2RY4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.